[HTML][HTML] Addition of bevacizumab to erlotinib as first-line treatment of patients with EGFR-mutated advanced nonsquamous NSCLC: the BEVERLY multicenter …
MC Piccirillo, L Bonanno, MC Garassino… - Journal of Thoracic …, 2022 - Elsevier
Introduction Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of
patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited …
patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited …
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter …
MC Piccirillo, L Bonanno… - Journal of thoracic …, 2022 - pubmed.ncbi.nlm.nih.gov
Introduction Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of
patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited …
patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited …
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter …
MC Piccirillo, L Bonanno, MC Garassino… - Journal of Thoracic …, 2022 - europepmc.org
Methods Eligible patients were randomized 1: 1 to erlotinib plus bevacizumab or erlotinib
alone. Investigator-assessed PFS and blinded independent centrally reviewed PFS were …
alone. Investigator-assessed PFS and blinded independent centrally reviewed PFS were …
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter …
MC Piccirillo, L Bonanno, MC Garassino… - JOURNAL OF …, 2022 - iris.unicampania.it
Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of patients with
EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited data were …
EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited data were …
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter …
MC Piccirillo, L Bonanno, MC Garassino… - JOURNAL OF …, 2022 - research.unipd.it
Introduction: Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of
patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited …
patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited …
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter …
MC Piccirillo, L Bonanno, MC Garassino… - Journal of Thoracic …, 2022 - jto.org
Introduction Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of
patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited …
patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited …
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter …
MC Piccirillo, L Bonanno, MC Garassino… - JOURNAL OF …, 2022 - iris.unicampus.it
Introduction: Adding bevacizumab to erlotinib prolonged progression-free survival (PFS) of
patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited …
patients with EGFR-mutated advanced NSCLC in the Japanese JO25567 trial, but limited …